Ask AI

H3 K27–Altered Diffuse Midline Glioma From Biopsy to Treatment: Neurosurgical Decisions in the Era of Molecularly Directed Therapy

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 20, 2026

Expiration: May 19, 2027

See Activity Collection

In this on-demand webinar on the neurosurgical management of H3 K27–altered diffuse midline glioma (DMG), expert faculty focus on the role of stereotactic biopsy, molecular diagnosis, and treatment planning. Topics include evaluating the risks and benefits of tissue acquisition based on tumor location and clinical presentation; optimizing biopsy techniques and tissue stewardship to support integrated molecular diagnosis; and interpreting H3 K27M immunohistochemistry, H3K27me3 assessment, sequencing, and cerebrospinal fluid tumor DNA testing. The slides also review clinical evidence supporting dordaviprone in progressive H3 K27–mutant DMG, the ongoing phase III ACTION trial, and investigational approaches including ONC206 and CAR T-cell therapies targeting GD2 and B7-H3. Additional considerations include managing neurologic deterioration and hydrocephalus, coordinating multidisciplinary care, and optimizing referral timing and procedural planning to preserve treatment and clinical trial opportunities.

DMG From Biopsy to Treatment

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many patients with diffuse midline glioma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Given lack of neurologic deficits and excellent functional status without focal deficits, what would you recommend to the family at this time?

How confident are you in your answer?
4.

What therapeutic interventions/clinical recommendations would you make for this patient? 

How confident are you in your answer?
5.

Which of the following is the most appropriate next step in managing this patient?

How confident are you in your answer?